NIH Funding

I fully agree with T.V. Rajan's Commentary on funding.1 Regrettably, he is also right about being a hopeless 19th-century romantic. This is because he and many others like him, including me, do not possess the influence to change the trend that has afflicted science and its funding for the past two decades: commercialism. As in other domains where public funds are used, those in charge of these funds believe that their foremost responsibility is to show a fast and hefty return on their investm

Written byAvital Schurr
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

I fully agree with T.V. Rajan's Commentary on funding.1 Regrettably, he is also right about being a hopeless 19th-century romantic. This is because he and many others like him, including me, do not possess the influence to change the trend that has afflicted science and its funding for the past two decades: commercialism.

As in other domains where public funds are used, those in charge of these funds believe that their foremost responsibility is to show a fast and hefty return on their investments. A descriptive study is not a good return. Even a hypothesis-driven study is not a good return anymore. In today's atmosphere, a grant application better propose a vaccine against a virus of which the infection mechanism is yet to be understood, or a treatment for a disorder not yet fully elucidated--a proposal with an outcome of commercial value.

Thus, the scientist of today is measured by ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies